The specific property of a PCSK9 vaccine is able to induce the host to generate anti-PCSK9 antibodies that can disrupt the interaction between PCSK9 and LDLR.228 To this end, L-IFPTA (liposomal immunogenic fused PCSK9-tetanus peptide plus Alum adjuvant) is a recently designed novel PCSK9 vaccine.229 L-IFPTA vaccine contains a PCSK9 sequence as a B-cell epitope, and a T-helper cell epitope belonging to tetanus toxin proteins. The gene discussed is PCSK9; the disease is tetanus.